Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT03781063 is registered in ClinicalTrials.gov with Sermonix Pharmaceuticals Inc. as lead sponsor.

NCT NCT03781063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03781063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Lead sponsor
Sermonix Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 20, 2019
Completion date
May 8, 2025
Enrollment
100 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic breast cancer